Piotrekswat/iStock via Getty Images Cidara Therapeutics (NASDAQ:CDTX) said it has received an $11.14M milestone payment from partner Mundipharma related to the European approval of its antifungal drug Rezzayo for the treatment of invasive candidiasis in adults. Cidara said the payment will help advance its Cloudbreak platform for the development of drug-Fc conjugates, a type of targeted immunotherapy.

Piotrekswat/iStock通过Getty Images Cidara Therapeutics（NASDAQ:CDTX）表示，已收到合作伙伴Mundipharma支付的1114万美元里程碑式款项，该款项与欧洲批准其抗真菌药物Rezzayo用于治疗成人侵袭性念珠菌病有关。Cidara表示，这笔款项将有助于推进其Cloudbreak平台开发药物Fc结合物，这是一种靶向免疫疗法。

Reyazzo is already approved by the FDA for the treatment of candidemia and invasive candidiasis in patients with few or no treatment options. The product received UK regulatory approval in late January. More on Cidara Therapeutics Cidara rallies 13% after hours on UK approval for Rezzayo Cidara, Melinta announce publication of Rezzayo data in medical journal Seeking Alpha’s Quant Rating on Cidara Therapeutics Historical earnings data for Cidara Therapeutics Financial information for Cidara Therapeutics .

Reyazzo已经被FDA批准用于治疗很少或没有治疗选择的患者的念珠菌病和侵袭性念珠菌病。该产品于1月底获得英国监管部门的批准。关于Cidara Therapeutics的更多信息英国批准Rezzayo Cidara后，Cidara上涨了13%，Melinta在医学杂志上公布了Rezzayo数据，寻求Alpha对Cidara Therapeutics历史收益数据的定量评级Cidara Therapeutics的财务信息。